secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001213900-25-018776
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron FY2024 revenue up 237% to $2.4M; net loss narrows 25% to $16.0M
--------------------------------------------------------------------------

- Total revenue $2.4M (FY2023: $0.7M) driven by Bahamas Registry Trial and new manufacturing contract.
- Net loss $16.0M vs $21.4M in 2023; cash & equivalents $19.2M, runway into Q4 2025.
- Pivotal ELPIS II HLHS trial >90% enrolled; enrollment expected to complete Q2 2025.
- BLA submission for Lomecel-B (laromestrocel) in HLHS anticipated in 2026 if trial successful.
- FDA meeting for mild Alzheimer’s disease pathway expected late Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390025018776/0001213900-25-018776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390025018776/ea0232284-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-018776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer